---
figid: PMC5410960__115512fig16
figlink: /pmc/articles/PMC5410960/figure/fig16/
number: F16
caption: Top illustration shows disruptions in normal cell survival and normal apoptosis
  in glioblastoma. A combination of pro–cell survival and antiapoptotic events triggers
  resistance to death-inducing stimuli, and increased activity of PI3K—by way of extracellular
  factors (eg, EGF and PDGF) or inherently abnormal RTKs (eg, constitutively active
  EGFRvIII mutant)—leads to increased downstream pathway signaling effects. Decreased
  proapoptotic activity in the extrinsic and intrinsic apoptosis pathways is a substantial
  contributor to enhanced survival. Bottom illustration shows therapeutic agents used
  to target contributors to cell survival and antiapoptosis, which overlap those used
  in antiangiogenesis and antiproliferation therapies and include receptor inhibitors
  and inhibitors of Akt and mTOR. Other newer strategies include targeting the apoptosis
  pathway with gossypol, adenoviral p53 therapy to restore tumor suppressor activity,
  and recombinant TNF-related apoptosis-inducing ligand (TRAIL). Bcl-2 = B-cell lymphoma
  2 oncogene, TNFR1 = tumor necrosis factor R1, TP53 = mutant tumor p53.
pmcid: PMC5410960
papertitle: 'Genetics of Glioblastoma: A Window into Its Imaging and Histopathologic
  Variability.'
reftext: Clifford J. Belden, et al. Radiographics.  October 2011;31(6):1717-1740.
pmc_ranked_result_index: '141946'
pathway_score: 0.9446537
filename: 115512fig16.jpg
figtitle: Top illustration shows disruptions in normal cell survival and normal apoptosis
  in glioblastoma
year: ''
organisms: Homo sapiens
ndex: f09d4eae-defb-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5410960__115512fig16.html
  '@type': Dataset
  description: Top illustration shows disruptions in normal cell survival and normal
    apoptosis in glioblastoma. A combination of pro–cell survival and antiapoptotic
    events triggers resistance to death-inducing stimuli, and increased activity of
    PI3K—by way of extracellular factors (eg, EGF and PDGF) or inherently abnormal
    RTKs (eg, constitutively active EGFRvIII mutant)—leads to increased downstream
    pathway signaling effects. Decreased proapoptotic activity in the extrinsic and
    intrinsic apoptosis pathways is a substantial contributor to enhanced survival.
    Bottom illustration shows therapeutic agents used to target contributors to cell
    survival and antiapoptosis, which overlap those used in antiangiogenesis and antiproliferation
    therapies and include receptor inhibitors and inhibitors of Akt and mTOR. Other
    newer strategies include targeting the apoptosis pathway with gossypol, adenoviral
    p53 therapy to restore tumor suppressor activity, and recombinant TNF-related
    apoptosis-inducing ligand (TRAIL). Bcl-2 = B-cell lymphoma 2 oncogene, TNFR1 =
    tumor necrosis factor R1, TP53 = mutant tumor p53.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - BCL2
  - LTB
  - TNFRSF1A
  - TP53
  - PIK3R3
  - FAS
  - AKT1
  - PIK3R4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - EGF
  - TNFSF10
  - PDGFA
  - FASLG
  - GNB5
  - GNB3
  - GNB4
  - AKT3
  - MTOR
  - NFKB1
  - NFKB2
  - TNFRSF10A
  - TNFRSF21
  - RELB
  - EGFR
  - PDGFC
  - PDGFD
  - GNB1
  - GNB2
  - PIK3R6
  - PIK3R5
  - PDGFRA
  - REL
  - RELA
  - PDGFRB
  - PDGFB
  - Perifosine
  - Temsirolimus
  - Gossypol
  - Nelfinavir
  - Cancer
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Bcl-2
  symbol: Bcl-2
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: TNFC
  symbol: TNFC
  source: hgnc_prev_symbol
  hgnc_symbol: LTB
  entrez: '4050'
- word: TNFR1
  symbol: TNFR1
  source: hgnc_prev_symbol
  hgnc_symbol: TNFRSF1A
  entrez: '7132'
- word: TP53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: FAS
  symbol: FAS
  source: hgnc_symbol
  hgnc_symbol: FAS
  entrez: '355'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: TRAIL
  symbol: TRAIL
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF10
  entrez: '8743'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: FASL
  symbol: FasL
  source: hgnc_alias_symbol
  hgnc_symbol: FASLG
  entrez: '356'
- word: GB
  symbol: G_beta
  source: bioentities_symbol
  hgnc_symbol: GNB5
  entrez: '10681'
- word: GB
  symbol: G_beta
  source: bioentities_symbol
  hgnc_symbol: GNB3
  entrez: '2784'
- word: GB
  symbol: G_beta
  source: bioentities_symbol
  hgnc_symbol: GNB4
  entrez: '59345'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: DR4/DR6
  symbol: DR4
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF10A
  entrez: '8797'
- word: DR4/DR6
  symbol: DR6
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF21
  entrez: '27242'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: GB
  symbol: G_beta
  source: bioentities_symbol
  hgnc_symbol: GNB1
  entrez: '2782'
- word: GB
  symbol: G_beta
  source: bioentities_symbol
  hgnc_symbol: GNB2
  entrez: '2783'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
chemicals:
- word: Perifosine
  source: MESH
  identifier: C105905
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Gossypol
  source: MESH
  identifier: D006072
- word: Nelfinavir
  source: MESH
  identifier: D019888
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5410960__F16
redirect_from: /figures/PMC5410960__F16
figtype: Figure
---
